SCHEMBL20911641

SCHEMBL20911641

O=c1[nH]cnc2c(-c3cccc(OCCO)c3)cn(-c3ccccc3)c12

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SRC P12931 2/20 0.48
MAPT P10636 6/20 0.45
KMT2A Q03164 4/20 0.44
LMNA P02545 3/20 0.44
PKM P14618 1/20 0.44
GAA P10253 1/20 0.42
HTT P42858 1/20 0.42
BRD4 O60885 2/20 0.40
FABP4 P15090 2/20 0.39
FABP3 P05413 1/20 0.39
MEN1 O00255 3/20 0.38
FABP5 Q01469 1/20 0.38
UBE2N P61088 1/20 0.37
PDPK1 O15530 1/20 0.37
ADORA3 P0DMS8 1/20 0.37
ABL1 P00519 1/20 0.37
EGFR P00533 1/20 0.37
CDK1 P06493 1/20 0.37
ABL2 P42684 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20912340 0.89 MAPT (0.51) SRCMAPTKMT2ALMNAPKM
SCHEMBL20912337 0.85 MAPT (0.49) SRCMAPTKMT2ALMNAPKM
SCHEMBL22604364 0.84 SRC (0.71) SRCMAPTKMT2ALMNAPKM
SCHEMBL8819526 0.84 SRC (0.64) SRCMAPTKMT2ALMNAPKM
SCHEMBL20912011 0.84 SRC (0.51) SRCMAPTKMT2ALMNAPKM
SCHEMBL20898225 0.82 SRC (0.50) SRCMAPTKMT2ALMNAPKM
SCHEMBL30662364 0.82 SRC (0.50) SRCMAPTKMT2ALMNAPKM
SCHEMBL20911860 0.81 SRC (0.49) SRCMAPTKMT2ALMNAPKM
SCHEMBL22604453 0.81 FYN (0.46) SRCMAPTKMT2ALMNAGAA
SCHEMBL20912038 0.80 MAPT (0.56) SRCMAPTKMT2ALMNAPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11795169-B2 MAP4K4 inhibitors IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2023-10-24 US disclosed
US-11795169-B2 MAP4K4 inhibitors IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2023-10-24 US disclosed
US-20200339583-A1 MAP4K4 INHIBITORS IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2020-10-29 US disclosed
WO-2019073253-A1 MAP4K4 INHIBITORS IMPERIAL INNOVATIONS LIMITED (GB) 2019-04-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200339583-A1 MAP4K4 INHIBITORS MAP4K4, MAP4K2, MAP4K5 SRC 594/4885MAPT 315/4885KMT2A 1775/4885
US-11795169-B2 MAP4K4 inhibitors MAP4K4, MAP4K2, MAP4K5 SRC 594/4885MAPT 315/4885KMT2A 1775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.